253.96
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $253.96, with a volume of 2.04M.
It is up +1.03% in the last 24 hours and up +2.23% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$250.91
Open:
$251.23
24h Volume:
2.04M
Relative Volume:
0.34
Market Cap:
$448.84B
Revenue:
$62.82B
Net Income/Loss:
$3.60B
P/E Ratio:
125.26
EPS:
2.0274
Net Cash Flow:
$19.98B
1W Performance:
-2.58%
1M Performance:
+2.23%
6M Performance:
+11.67%
1Y Performance:
+19.78%
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
ABBV
Abbvie Inc
|
254.00 | 443.39B | 62.82B | 3.60B | 19.98B | 2.0274 |
|
LLY
Lilly Eli Co
|
1,124.04 | 1.00T | 72.25B | 25.28B | 10.37B | 27.78 |
|
JNJ
Johnson Johnson
|
266.68 | 643.64B | 97.93B | 21.04B | 17.80B | 8.6278 |
|
MRK
Merck Co Inc
|
144.72 | 363.98B | 65.51B | 8.93B | 14.12B | 3.5532 |
|
NVS
Novartis Ag Adr
|
137.77 | 261.31B | 54.66B | 13.58B | 16.05B | 7.0171 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Aug-05-26 | Upgrade | Erste Group | Hold → Buy |
| Apr-30-26 | Upgrade | BofA Securities | Neutral → Buy |
| Apr-21-26 | Initiated | Canaccord Genuity | Buy |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-08-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-04-25 | Downgrade | DZ Bank | Buy → Hold |
| Oct-14-25 | Downgrade | Erste Group | Buy → Hold |
| Oct-01-25 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
AbbVie declares quarterly dividend of $1.73 per share By Investing.com - Investing.com India
AbbVie Declares Quarterly Dividend - Yahoo Finance
AbbVie Gains as Qulipta Opens a New Migraine Market - Yahoo! Finance Canada
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
AbbVie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine - Investing News Network
AbbVie reports positive Phase 3 migraine trial results - grafa.com
AbbVie Drug Shows Significant Reductions in Menstrual Migraine Days - Benzinga
AbbVie Inc. stock gains as atogepant trial success and HSBC target hike reinforce growth story - ad-hoc-news.de
AbbVie's Immunology Franchise: From Skyrizi & Rinvoq to What's Next - Yahoo Finance
ABBV Maintained by HSBC -- Price Target Raised to $315 - GuruFocus
AbbVie's menstrual migraine treatment meets late-stage study goal - Reuters
Why Has AbbVie Gone Quiet About Humira? - Trefis
ADARx Pharmaceuticals Seeks IPO On Strong Collaboration Deal With AbbVie (Pending:ADRX) - Seeking Alpha
AbbVie’s migraine treatment meets late-stage study goal - 1450 AM 99.7 FM WHTC
AbbVie reports positive phase 3 trial for menstrual migraine drug By Investing.com - Investing.com Canada
UChicago Medicine names Kimyatta Washington Chief Operating Officer of AbbVie Foundation Cancer Pavilion | Newswise - Newswise
Here’s How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years - Benzinga
Is AbbVie (ABBV)’s $10.9 Billion Apogee Therapeutics (APGE) Deal the Next Catalyst for Growth? - Yahoo Finance
AbbVie Highlights SKYRIZI, RINVOQ Growth and Pipeline Catalysts at Wells Fargo Conference - Yahoo Finance
AbbVie at Wells Fargo healthcare conference: growth beyond immunology By Investing.com - Investing.com UK
ABBV: Immunology, oncology, and neuroscience pipelines advance with strong data and strategic investments - TradingView
2 Dividend Stocks Built to Hold Up When Markets Don't - The Motley Fool
AbbVie stock slips as Q2 revenue rises 10.2 percent - ad-hoc-news.de
AbbVie issues US$10 billion to fund Apogee acquisition - fi-desk.com
AbbVie stock heads into the open after a 2.99 percent drop - ad-hoc-news.de
AbbVie (ABBV) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance
Apogee Therapeutics (NASDAQ: APGE) leaves Nasdaq in AbbVie cash buyout - Stock Titan
Why Did AbbVie (NYSE:ABBV) Just Close Its Biggest Deal In Years? - Kalkine Media
Is AbbVie Stock Too Reliant On Skyrizi? - Trefis
AbbVie Inc. stock edges lower as investors weigh strong earnings and higher analyst targets - ad-hoc-news.de
BofA Securities Upgrades AbbVie(ABBV.US) to Buy Rating, Raises Target Price to $282 - Moomoo
BofA Securities Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $282 - Moomoo
BofA raises Abbvie stock price target on Apogee deal close By Investing.com - Investing.com India
BofA raises Abbvie stock price target on Apogee deal close - Investing.com
AbbVie’s Next Skyrizi Catalyst Lands This Fall. Here’s What’s at Stake for the Stock - TIKR.com
AbbVie Inc. (ABBV) Stock Analysis: Exploring Growth Potential Amidst A Solid 7.85% Upside - DirectorsTalk Interviews
What Does Friday’s Close Mean for AbbVie (NYSE:ABBV) and NYSE? - Kalkine Media
Mary Kuriakose Starts New Oncology Leadership Role at AbbVie - Oncodaily
AbbVie Inc. stock holds near highs as Apogee deal and guidance support sentiment - ad-hoc-news.de
Key deals this week: Flex, Nvidia, AbbVie and more (VRT:NYSE) - Seeking Alpha
Michael Henderson: A New Chapter Begins for Apogee Therapeutics With AbbVie - Oncodaily
Scotiabank Remains a Buy on AbbVie (ABBV) - The Globe and Mail
AbbVie-allied ADARx aims to go public with 3 drugs in the clinic - Endpoints News
Atopic Dermatitis Drugs Market Set to Reach USD 33.42 Billion by 2035, at a CAGR of 7.70% - GlobeNewswire Inc.
AbbVie Inc. stock underperforms Friday when compared to competitors - MarketWatch
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Trailing rivals, AbbVie scores win with dual-acting myeloma drug - BioPharma Dive
AbbVie Inc. stock gains on Apogee deal and reaffirmed 2026 guidance - ad-hoc-news.de
ABBV's Etentamig Meets Goals in Phase III Multiple Myeloma Study - Yahoo Finance
AbbVie’s Humira Cash Cow Is Shrinking—Can Its Dividend Keep Growing? - finance.yahoo.com
AbbVie (ABBV) Reports Positive Phase 3 Results For Etentamig In Multiple Myeloma - finance.yahoo.com
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):